Geoffrey I. Shapiro, MD, PhD
Associate Professor, Department of Medicine, Harvard Medical School
Associate Professor, Medical Oncology, Dana-Farber Cancer Institute
Director, Early Drug Development Center, Dana-Farber Cancer Institute
DF/HCC Program AffiliationTranslational Pharmacology and Early Therapeutic TrialsLung Cancer
Member, Clinical Science Coordinating Committee
I conduct both basic and translational research on cyclin-dependent kinase inhibitors. A major goal is to define the role of one of these inhibitors, p16ink4a in the cellular response to DNA damage. In addition, I am directing both preclinical and clinical studies of several potent pharmacologic cyclin-dependent kinase inhibitors. Several phase I trials are underway investigating these agents in patients with advanced solid tumors. The work involves the assessment of these drugs alone, as well as in combination with standard chemotherapy agents and signal transduction inhibitors.
View All Publications